ArticleInternational urology and nephrology2018
Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study.
Article in International urology and nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Analysis of Skeletal-Related Events in a Liaison Treatment for Metastatic Spinal Tumors: A 10-Year Retrospective Study.Spine surgery and related research · 2026Article
- Development and external validation of a nomogram to predict the prognosis of patients with metastatic prostate cancer who underwent radiotherapy.Gland surgery · 2024Article
- Assessing the Efficacy of a 28-Day Comprehensive Online Prostate Cancer Patient Empowerment Program (PC-PEP) in Facilitating Engagement of Prostate Cancer Patients in Their Survivorship Care: A Qualitative Study.Current oncology (Toronto, Ont.) · 2023Article
- Survival trends for patients with primary metastatic prostate cancer before and after the introduction of new antitumor drugs.Prostate cancer and prostatic diseases · 2023Article
- Effectiveness of Rehabilitation for Cancer Patients with Bone Metastasis.Progress in rehabilitation medicine · 2022Article
- Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second-line antiandrogen therapy era.Cancer medicine · 2021Article
- Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients.Frontiers in oncology · 2021Article
- Article
- Prostate carcinogenesis: inflammatory storms.Nature reviews. Cancer · 2020Review
- Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer.Cancers · 2019Review
- Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.The journal of sexual medicine · 2019Article
- Abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 'real-life' studies.Therapeutic advances in urology · 2018Article
- Emerging role of cytoreductive prostatectomy in patients with metastatic disease.Translational andrology and urology · 2018Review
- Review
- Impact of a Specialized Outpatient Clinic on Bone Metastasis and Its Burden on Spine Surgeons.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesOver the past decade, several systemic agents as docetaxel, cabazitaxel, sipuleucel-T, abiraterone and enzalutamide have improved overall survival (OS) in metastatic prostate cancer (mPCa) patients. However, to date the OS benefit was not demonstrated in population-based analysis.
methodsBetween 2004 and 2014, 19,047 men with de novo mPCa were identified within the Surveillance Epidemiology and End Results database. Median year of diagnosis resulted in two groups: historical (2004-2008) and contemporary (2009-2014). Due to potentially important differences according to year of diagnosis, we relied on propensity score matching. Propensity-score-matched Kaplan-Meier analyses and Cox regression models (CRMs) tested cancer-specific mortality (CSM) free survival and overall mortality (OM) free survival according to treatment period.
resultsThe propensity-score-matched cohort consisted of 8596 patients with mPCa. Of those, 4298 (50.0%) were historical (2004-2008) and 4298 (50.0%) were contemporary (2009-2014). CSM free survival rates and OM free survival rate were 32 versus 36 months (p < 0.0001) and 26 versus 29 months (p < 0.0001) for, respectively, historical and contemporary patients. In multivariable CRMs, patients diagnosed in contemporary years had lower CSM (HR 0.88; CI 0.82-0.93) and OM (HR 0.88; CI 0.84-0.93) risks compared to historical counterpart (all p < 0.0001).
conclusionThis population-based study provides the first evidence of improved CSM free survival and OM free survival in patients with de novo mPCa since the introduction of several systemic agents for CRPC patients.
Indexed as
Identifiers
29129028What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.